Inclusion Criteria:

• RPE65-associated retinal disease (two disease-causing RPE65 mutations);
• Clinical diagnosis of Leber congenital amaurosis (LCA)/early-onset retinal degeneration (EORD) and of severely impaired visual and retinal function, and best corrected visual acuity of 20/50 or worse in the study eye;
• Ability to perform tests of visual and retinal function;
• Visible photoreceptor layer on a standard OCT scan;
• Good general health;
• Ability to comply with research procedures;
• Specific for Cohorts 1 and 2: 18 years of age and older;
• Specific for Cohort 3: Between 8 and 17 years of age, inclusive.

Exclusion Criteria:

• AAV antibody titers greater than two standard deviations above normal at baseline;
• Humoral immune deficiency as evidenced by low tetanus toxoid IgG antibody titers;
• Pre-existing eye conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints or surgical complications;
• chorioretinal atrophy;
• Complicating systemic diseases;
• Use of anti-platelet agents that may alter coagulation within 7 days prior to study agent administration;
• Use of immunosuppressive medications;
• Pregnancy or breastfeeding;
• Individuals (males and females) of childbearing potential who are unwilling to use effective contraception;
• Any condition that would prevent a subject from completing follow-up examinations during the course of the study;
• Any condition that makes the subject unsuitable for the study;
• Current, or recent participation, in any other research protocol involving investigational agents or therapies;
• Recent receipt of an investigational biologic therapeutic agent.